Diffusion Basis Spectrum Imaging of the Prostate

Diffusion Basis Spectrum Imaging of the Prostate: A Virtual Biopsy to Accurately Diagnose Prostate Cancer

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

Inclusion Criteria:

• Over 18 years of age and willing and able to provide informed consent.

• Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate biopsy as clinical standard of care ("early detection cohort")

• Including those men with:

  • an elevated PSA and no prior biopsy
  • an elevated PSA and a negative prior biopsy

• Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")

Exclusion Criteria:

• Patients with any clinical contraindication to MRI

  *Including but not limited to:

  • Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
  • Those with cochlear implants
  • Those with claustrophobia not relieved with medications (patients with claustrophobia who do not need medications for the scan or whose claustrophobia can be managed with medication, are eligible to participate)
  • Those who cannot lie flat for over 1 hour

• Patients with prior prostate surgery for prostate cancer (e.g. radical prostatectomy, focal ablation)